Bluejay Diagnostics (NASDAQ:BJDX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Bluejay Diagnostics (NASDAQ:BJDX) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics presently has a consensus rating of “Sell”.

Bluejay Diagnostics Trading Down 0.9%

Shares of NASDAQ:BJDX opened at $1.05 on Friday. Bluejay Diagnostics has a 12 month low of $0.83 and a 12 month high of $16.68. The company has a market capitalization of $1.09 million, a price-to-earnings ratio of -0.09 and a beta of 0.89. The firm’s 50-day moving average is $2.08 and its 200 day moving average is $2.20.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.88.

Insider Buying and Selling at Bluejay Diagnostics

In related news, major shareholder Financial Lp Hrt sold 34,938 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the sale, the insider owned 92,055 shares in the company, valued at approximately $128,877. The trade was a 27.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is owned by hedge funds and other institutional investors.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.